We could not find any results for:
Make sure your spelling is correct or try broadening your search.
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy New data from the RESPOND...
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting New data advances understanding of new approaches to treating...
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of...
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating...
Biogen to Realign Resources for Alzheimer's Disease Franchise Company to reprioritize resources allocated to ADUHELM® (aducanumab-avwa) to advance LEQEMBI® (lecanemab-irmb) and to develop new...
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB...
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease Friedreich’s ataxia is a genetic...
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. ZURZUVAE, the first and only oral, once-daily, 14-day treatment...
ame of Sage Therapeutics Inc. Please ignore incorrect coding of Shield Therapeutics PLC.) (Alliance News) - The US Fo ...
The US Food & Drug Administration has approved Zurzuvae, zuranolone, 50 mg for adults with postpartum depression, Sag ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 277.67 | 277.67 | 277.67 | 2128 | 277.67 | DE |
4 | 0 | 0 | 277.67 | 277.67 | 277.67 | 1666 | 277.67 | DE |
12 | 0 | 0 | 277.67 | 277.67 | 277.67 | 2158 | 277.67 | DE |
26 | 0 | 0 | 277.67 | 277.67 | 277.67 | 3155 | 277.67 | DE |
52 | 0 | 0 | 277.67 | 277.67 | 277.67 | 4304 | 277.67 | DE |
156 | 0 | 0 | 277.67 | 277.67 | 277.67 | 4969 | 277.67 | DE |
260 | 0 | 0 | 277.67 | 277.67 | 277.67 | 5112 | 277.67 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions